公开(公告)号：US20060025410A1

公开(公告)日：2006-02-02

申请号：US11149105

申请日：2005-06-08

申请人： Rajinder Singh ,  Ankush Argade ,  Donald Payan ,  Susan Molineaux ,  Sacha Holland ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander Rossi

发明人： Rajinder Singh ,  Ankush Argade ,  Donald Payan ,  Susan Molineaux ,  Sacha Holland ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander Rossi

IPC分类号： A61K31/538 ,  C07D413/02

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

公开(公告)号：US20050038243A1

公开(公告)日：2005-02-17

申请号：US10858343

申请日：2004-06-01

申请人： Rajinder Singh ,  Ankush Argade ,  Donald Payan ,  Susan Molineaux ,  Sacha Holland ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander Rossi

发明人： Rajinder Singh ,  Ankush Argade ,  Donald Payan ,  Susan Molineaux ,  Sacha Holland ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander Rossi

IPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61P1/00 ,  A61P11/06 ,  A61P17/00 ,  A61P27/02 ,  A61P27/14 ,  A61P27/16 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D239/48 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D513/02 ,  C07D498/02

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

摘要翻译： 本发明提供了抑制导致释放化学介质，中间体和合成化合物的方法的IgE和/或IgG受体信号级联的2,4-嘧啶二胺化合物和在多种情况下使用化合物的方法，包括 在治疗和预防以IgE和/或IgG受体信号传导级联的活化作用通过脱颗粒和其它方法释放化学介质引起或与之相关的疾病。

公开(公告)号：US08188276B2

公开(公告)日：2012-05-29

申请号：US12363537

申请日：2009-01-30

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G Payan ,  Susan Molineaux ,  Sasha J Holland ,  Jeffrey Wayne Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander B Rossi

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G Payan ,  Susan Molineaux ,  Sasha J Holland ,  Jeffrey Wayne Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li ,  Alexander B Rossi

IPC分类号： C07D239/02 ,  A61K31/505

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

摘要翻译： 本发明提供了抑制导致释放化学介质，中间体和合成化合物的方法的IgE和/或IgG受体信号级联的2,4-嘧啶二胺化合物和在多种情况下使用化合物的方法，包括 在治疗和预防以IgE和/或IgG受体信号传导级联的活化作用通过脱颗粒和其它方法释放化学介质引起或与之相关的疾病。

公开(公告)号：US20070299095A1

公开(公告)日：2007-12-27

申请号：US11539101

申请日：2006-10-05

申请人： Rajinder Singh ,  Ankush Argade ,  Donald Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： A61K31/505 ,  A61P37/00

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

公开(公告)号：US20070060603A1

公开(公告)日：2007-03-15

申请号：US10631029

申请日：2003-07-29

申请人： Rajinder Singh ,  Ankush Argade ,  Donald Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： A61K31/505

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮病和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：US20180072756A1

公开(公告)日：2018-03-15

申请号：US15468467

申请日：2017-03-24

申请人： Rajinder Singh ,  Ankush Argade ,  Hui Li ,  Somasekhar Bhamidipati ,  David Carroll ,  Catherine Sylvain ,  Jeffrey Clough ,  Holger Keim

发明人： Rajinder Singh ,  Ankush Argade ,  Hui Li ,  Somasekhar Bhamidipati ,  David Carroll ,  Catherine Sylvain ,  Jeffrey Clough ,  Holger Keim

IPC分类号： C07D498/04 ,  C07D498/06 ,  C07D417/14 ,  C07D417/12 ,  C07D413/14 ,  A61K31/506 ,  C07D405/14 ,  C07D405/12 ,  C07D403/12 ,  A61K31/541 ,  C07D413/12

CPC分类号： C07D498/04 ,  A61K31/506 ,  A61K31/538 ,  A61K31/541 ,  A61P19/02 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D498/02 ,  C07D498/06

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

公开(公告)号：US20120230984A1

公开(公告)日：2012-09-13

申请号：US13418696

申请日：2012-03-13

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： A61K31/506 ,  A61K31/5383 ,  A61K31/56 ,  A61K31/616 ,  A61K31/519 ,  A61P37/06 ,  A61P37/08 ,  A61K39/395 ,  A61P7/06 ,  A61P25/00 ,  A61P7/00 ,  A61P27/02 ,  A61P21/04 ,  A61P1/16 ,  A61P13/12 ,  A61P29/00 ,  A61P19/02 ,  A61P19/04 ,  A61K31/538

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮病和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：US08178671B2

公开(公告)日：2012-05-15

申请号：US10903263

申请日：2004-07-30

申请人： Rajinder Singh ,  Ankush Argade ,  Hui Li ,  Somasekhar Bhamidipati ,  David Carroll ,  Catherine Sylvain ,  Jeffrey Clough ,  Holger Keim

发明人： Rajinder Singh ,  Ankush Argade ,  Hui Li ,  Somasekhar Bhamidipati ,  David Carroll ,  Catherine Sylvain ,  Jeffrey Clough ,  Holger Keim

IPC分类号： C07D239/48 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D417/12 ,  A61K31/506 ,  A61K31/498 ,  A61K31/5375 ,  A61K31/5383 ,  A61K31/5415 ,  A61P19/02

CPC分类号： C07D498/04 ,  A61K31/506 ,  A61K31/541 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D498/06

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：US08158621B2

公开(公告)日：2012-04-17

申请号：US12691657

申请日：2010-01-21

申请人： Rajinder Singh ,  Ankush Argade ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： C07D498/04 ,  A61K31/538

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮病和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：US07825116B2

公开(公告)日：2010-11-02

申请号：US11539101

申请日：2006-10-05

申请人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

发明人： Rajinder Singh ,  Ankush Argade ,  Donald G. Payan ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Catherine Sylvain ,  Hui Li

IPC分类号： C07D239/48 ,  C07D403/12 ,  A61K31/506

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04 ,  Y10S514/825 ,  Y10S514/903

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供了用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮病和/或其相关症状和多发性硬化症和/或其相关症状。